16 completed, 3 unknown, 2 terminated, 1 recruiting. 22 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 16, Unknown 3, Terminated 2, Recruiting 1 |
| Phase 2 | 8 | Completed 5, Unknown 2, Recruiting 1 |
Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-09-21 |
| To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | Grand Life Science (Liaoning) Co., Ltd. | 48 | 2020-10-21 | 2021-07-28 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis DS-2330b PIB, Placebo, Sevelamer - Hyperphosphatemia | Phase 1 | Completed | Daiichi Sankyo | 40 | 2017-08-17 | 2019-03-25 |
| A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis EOS789, Placebo, Renvela - Hyperphosphatemia | Phase 1 | Completed | Chugai Pharmaceutical | 26 | 2016-12-01 | 2018-09-13 |
| A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis VS-505 - End Stage Renal Disease, Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | KDL Inc. | 30 | 2015-06-01 | 2016-02-08 |
| A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 15 | 2014-07-01 | 2017-03-03 |
| Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan ASP3325 - Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis | Phase 1 | Completed | Astellas Pharma Inc | 24 | 2014-05-12 | 2024-11-05 |
| Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects colestilan, candesartan - Hyperphosphatemia, Chronic Kidney Disease | Phase 1 | Completed | Tanabe Pharma Corporation | 18 | 2013-10-01 | 2026-01-07 |
| Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Osteomalacia - Osteomalacia | Phase 1 | Terminated | National Institute of Dental and Craniofacial Research (NIDCR) | 1 | 2012-11-16 | 2018-07-05 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 23 | 2012-02-01 | 2024-06-18 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 29 | 2011-04-01 | 2024-06-18 |
| Bioequivalence Study of BAY77-1931 Granule Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule, Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet - Hyperphosphatemia | Phase 1 | Completed | Bayer | 59 | 2010-01-01 | 2014-06-23 |
| Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia FOSTRAP Chewing Gum, Placebo chewing gum - Hyperphosphatemia, Chronic Kidney Disease | Phase 1 | Completed | Denver Nephrologists, P.C. | 121 | 2010-01-01 | 2011-01-07 |
| A Study of KRN23 in X-linked Hypophosphatemia Placebo, KRN23 - X-linked Hypophosphatemia | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 42 | 2008-12-01 | 2024-06-17 |
| Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets - Hyperphosphatemia | Phase 1 | Completed | Fresenius Medical Care North America | 46 | 2008-08-01 | 2009-02-09 |
| Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. Sorafenib (Nexavar, BAY43-9006) - Carcinoma, Renal Cell | Phase 1 | Terminated | Bayer | 12 | 2008-05-01 | 2014-12-18 |
| The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Niacinamide, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 17 | 2006-10-01 | 2007-07-30 |
| The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients Niacinamide - Hyperphosphatemia | Phase 1 | Completed | Washington University School of Medicine | 40 | 2006-04-01 | 2009-01-16 |
| Growth Hormone Treatment in Children With Hypophosphatemic Rickets norditropine simplex - X Linked Hypophosphatemic Rickets | Phase 1 / Phase 2 | Completed | Bicetre Hospital | 19 | 2006-01-01 | 2016-03-28 |
Showing 20 of 22. Sign in to see all of them.
Hyperphosphatemia (11) · Familial Hypophosphatemic Rickets (9) · Kidney Failure, Chronic (3) · Renal Insufficiency, Chronic (3) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Hypophosphatemia (2) · Osteomalacia (2) · Rickets, Hypophosphatemic (2) · Bone Diseases (1) · Carcinoma, Renal Cell (1) · Growth Disorders (1) · Kidney Diseases (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Oncogenic osteomalacia (1)
Nutritional and Metabolic Diseases (22) · Metabolic Diseases (21) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Male Urogenital Diseases (16) · Urogenital Diseases (16) · Urologic Diseases (16) · Kidney Diseases (15) · Avitaminosis (12) · Bone Diseases, Metabolic (12) · Calcium Metabolism Disorders (12) · Deficiency Diseases (12) · Malnutrition (12) · Nutrition Disorders (12)
burosumab (5) · Niacinamide (2) · Sevelamer (2) · lanthanum carbonate (2) · ASP3325 (1) · Calcium Citrate (1) · Cinacalcet (1) · Growth Hormone (1) · Human Growth Hormone (1) · Sorafenib (1) · calcium acetate (1) · candesartan (1) · cholebine (1)
Kyowa Kirin Co., Ltd. (5) · Bayer (2) · Washington University School of Medicine (2) · Astellas Pharma Inc (1) · Bicetre Hospital (1) · Children's Mercy Hospital Kansas City (1) · Chugai Pharmaceutical (1) · Daiichi Sankyo (1) · Denver Nephrologists, P.C. (1) · Fresenius Medical Care North America (1) · Grand Life Science (Liaoning) Co., Ltd. (1) · KDL Inc. (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Tanabe Pharma Corporation (1)
United States (13) · Canada (3) · Japan (3) · France (2) · Germany (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · China (1) · Italy (1) · South Korea (1) · Sweden (1)
Amy Zhang, PhD (2) · Antoinette A. Pragalos, MD (1) · Daniel O Young, MD (1) · Daniel W Coyne, M.D> (1) · Dieter Haffner, MD (1) · Dirk Schnabel, MD (1) · Geoffrey A Block, MD (1) · Hagen Staude (1) · Jim Bush, Dr (1) · Johan Rosman, MD, Ph.D (1)
PMID 40576086, PMID 25919461, PMID 18385391, PMID 19776051, PMID 23797006, PMID 24569459, PMID 26073451, PMID 28822957, PMID 39151033, PMID 42044650